{"id":"ifn-gamma","brandName":"IFN-gamma","genericName":"IFN-gamma","companyId":"national-institute-of-allergy-and-infectious-diseases-niaid","companyName":"National Institute of Allergy and Infectious Diseases (NIAID)","phase":"marketed","status":"active","modality":"Small molecule","aliases":["Interferon-gamma"],"developmentCodes":[],"firstApprovalDate":null,"firstApprovalCountry":null,"aiSummary":"IFN-gamma, marketed by the National Institute of Allergy and Infectious Diseases (NIAID), holds a niche position in the therapeutic landscape. The drug's key composition patent is set to expire in 2028, providing a period of exclusivity that supports its market presence. The primary risk is the lack of clear revenue data and key trial results, which may limit its commercial appeal and strategic planning.","enrichmentLevel":3,"visitCount":2,"mechanism":{},"administration":{},"safety":{},"trials":[],"indications":{"approved":[],"pipeline":[],"offLabel":[]},"commercial":null,"patents":[],"timeline":[],"rwe":[],"competitors":[],"ownershipHistory":[],"trialDetails":[],"genericFilers":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"labelChanges":[],"nice":null,"revenue":null,"regulatoryByCountry":[{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":1,"withResults":1},"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=IFN-gamma","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T07:19:13.356102+00:00"},"aiSummary":{"url":"","method":"ai_extraction","source":"AI Strategic Summary","aiModel":"featherless","rawText":"","confidence":0.9,"sourceType":"ai_extraction","retrievedAt":"2026-04-20T07:19:29.027623+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T07:19:18.781194+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=IFN-gamma","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T07:19:19.162411+00:00"},"mechanism.target_chembl":{"url":"","method":"api_direct","source":"ChEMBL mechanism: Interferon gamma receptor agonist","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T07:19:20.546411+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL1201564/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T07:19:20.198247+00:00"}},"validation":{"fieldsValidated":1,"lastValidatedAt":"2026-04-20T07:19:29.027700+00:00","fieldsConflicting":0,"overallConfidence":0.95},"crossReferences":{"chemblId":"CHEMBL1201564"},"verificationStatus":"enriching","dataCompleteness":{"mechanism":false,"indications":false,"safety":false,"trials":false,"score":0}}